Tyverb wins EU approval for HER2-positive breast cancer

The European Commission granted conditional marketing authorisation to GlaxoSmithKline's breast cancer drug Tyverb (lapatinib). The company plans to make the product available as soon as possible.

Tyverb, in combination with Roche's Xeloda, is indicated for patients with HER2-positive advanced or metastatic breast cancer, and GlaxoSmithKline specified that patients should have progressive disease following therapy with anthracyclines and taxanes, as well as Roche's Herceptin in the metastatic setting. The once-daily product is the first oral targeted therapy available for patients with HER2-positive breast cancer in the EU, the company stated.

The drugmaker also noted that it will provide further clinical data to EU regulators and conduct an additional trial on the product.

To read more Top Story articles, click here.